Recursion OS: The AI product engine to industrialize drug discovery
Inside the loop: Learn how we map disease biology and design potential medicines, and carry them into the clinic — at scale
Take a look inside the automated labs that form our AI-native data factory to see our end-to-end drug discovery and development engine work as one connected system. Driven by bilingual teams of scientists and technologists, our wet and dry "lab-in-the-loop," forms a continuous learning system of physical automation and machine learning models. See how we run up to 2 million weekly experiments to build a 50+ petabyte proprietary dataset, tightly connecting biology, generative de novo chemistry, and translational clinical tools to systematically de-risk drug discovery.
Decoding biology to radically improve lives
As a top biotech — or TechBio — company, we're harnessing new technologies like advanced AI for drug discovery and drug development, supercomputing power, and automation, to build massive fit-for-purpose datasets and state-of-the-art multimodal machine learning foundation models.Our mission is to decode biology, taking a fundamentally different approach to traditional pharma, to design new drugs more efficiently and effectively.
The Recursion Operating System (OS), Recursion's proprietary AI drug discovery and drug development platform, spans target identification to clinical trial enrollment. Every data point we collect along the way is fed back into the drug discovery and drug development platform, improving its performance.
An end-to-end platform for AI drug discovery and development
Data is the foundation of the Recursion OS drug discovery and development system, underpinned by algorithms that can make predictions that will then be tested in our labs. Every physical experiment conducted is converted into digital representations of biology and chemistry, forming loops of physical data and digital analysis.
This approach allows us to iterate across the discovery process, leveraging machine learning and large language models (LLMs) built-for-purpose to uncover novel insights across biology and chemistry, fueling our clinical-stage pipeline.
Advancing a pipeline of first-in-class and best-in-class programs for oncology and rare disease
Today, Recursion is advancing a robust pipeline of clinical-stage assets. By leveraging Recursion’s vast data universe and machine learning models at every stage of the discovery, design and delivery process, we are able to rapidly validate and accelerate high-potential programs with both first- and best- in class properties.
Explore our full pipeline
